1887

Abstract

SUMMARY

Immunization strategies to prevent respiratory syncytial virus (RSV) disease will involve immunization of infants less than 2 months of age who possess maternally derived RSV antibodies. Vaccinia-RSV recombinant viruses are useful tools for defining parameters important in immunization against RSV and also are being considered as live virus vaccines for use in humans. Previous studies demonstrated that passively acquired RSV antibodies can suppress the immune response and the protective efficacy of vaccinia-RSV recombinants administered by the intradermal route. The present study demonstrates that the suppressive effects of passively acquired antibody on immunity induced by intradermally administered vaccinia-RSV recombinants in cotton rats can be partially overcome by administration of the recombinants by the intranasal route.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-70-8-2185
1989-08-01
2021-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/70/8/JV0700082185.html?itemId=/content/journal/jgv/10.1099/0022-1317-70-8-2185&mimeType=html&fmt=ahah

References

  1. Bangham C. R. M., Openshaw P. J. M., Ball L. A., King A. M. Q., Wertz G. W., Askonas B. A. 1986; Human and murine cytotoxic T cells specific for respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. Journal of Immunology 137:3973–3977
    [Google Scholar]
  2. Johnson M. P., Meitin C. A., Bender B. S., Small P. A. 1988; Passive immune serum inhibits antibody response to recombinant vaccinia virus. In Vaccines ’88: Modern Approaches to New Vaccines Including Prevention of Aids189–192 Chanock R. M. , Lerner R. A., Brown F., Ginsberg H. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  3. Kim H. W., Arrobio J. O., Brandt C. D., Jeffries B. C, Pyles G., Reid J. L., Chanock R. M., Parrott R. H. 1973; Epidemiology of respiratory syncytial virus infection in Washington D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. American Journal of Epidemiology 98:216–225
    [Google Scholar]
  4. Kimman T. G., Westenbrink F., Schreuder B. E. C., Straver P. J. 1987; Local and systemic antibody response to bovine respiratory syncytial virus infection and reinfection in calves with and without maternal antibodies. Journal of Clinical Microbiology 25:1097–1106
    [Google Scholar]
  5. Mclntosh K., Chanock R. M. 1985; Respiratory syncytial virus. In Virology1285–1304 Fields B. N. New York: Raven Press;
    [Google Scholar]
  6. Murphy B. R., Alling D. W., Snyder M. H., Walsh E. E., Prince G. A., Chanock R. M., Hemming V. G., Rodriguez W. J., Kim H. W., Graham B. S., Wright P. F. 1986; Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. Journal of Clinical Microbiology 24:894–898
    [Google Scholar]
  7. Murphy B. R., Graham S., Prince G. A., Walsh E. E., Chanock R. M., Karzon D. T., Wright P. F. 1986b; Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. Journal of Clinical Microbiology 23:1009–1014
    [Google Scholar]
  8. Murphy B. R., Prince G. A., Walsh E. E., Kim H. W., Parrott R. H., Hemming V. G., Rodriguez W. J., Chanock R. M. 1986; Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. Journal of Clinical Microbiology 24:197–202
    [Google Scholar]
  9. Murphy B. R., Olmsted R. A., Collins P. L., Chanock R. M., Prince G. A. 1988; Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. Journal of Virology 62:3907–3910
    [Google Scholar]
  10. Olmsted R. A., Elango N., Prince G. A., Murphy B. R., Johnson P. R., Moss B., Chanock R. M., Collins P. L. 1986; Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proceedings of the National Academy of SciencesU.S.A 83:7462–7466
    [Google Scholar]
  11. Olmsted R. A., Buller R. M. L., Murphy B. R., London W. T., Beeler J. A., Collins P. L. 1988; Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F and G glycoproteins of respiratory syncytial virus. In Vaccines ’88: Modern Approaches to New Vaccines Including Prevention of Aids205–210 Chanock R. M., Lerner R. A., Brown F., Ginsberg H. New York: Cold Spring Harbor Laboratory;
    [Google Scholar]
  12. Pemberton R. M., Cannon M. J., Openshaw P. J. M., Ball L. A., Wertz G. W., Askonas B. A. 1987; Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. Journal of General Virology 68:2177–2182
    [Google Scholar]
  13. Prince G. A., Jenson A. B., Hemming V. G., Murphy B. R., Walsh E. E., Horswood R. L., Chanock R. M. 1986; Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. Journal of Virology 57:721–728
    [Google Scholar]
  14. Ray R., Compans R. W. 1987; Glycoproteins of human parainfluenza virus type 3: affinity purification, antigenic characterization and reconstitution into lipid vesicles. Journal of General Virology 68:409–418
    [Google Scholar]
  15. Spriggs M. K., Murphy B. R., Prince G. A., Olmsted R. A., Collins P. L. 1987; Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. Journal of Virology 61:3416–3423
    [Google Scholar]
  16. Stott E. J., Ball L. A., Young K. K., Furze J., Wertz G. W. 1986; Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. Journal of Virology 60:607–613
    [Google Scholar]
  17. Walsh E. E., Schlesinger J. J., Brandriss M. W. 1984; Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infection and Immunity 43:756–758
    [Google Scholar]
  18. Walsh E. E., Hall C. B., Briselli M., Brandriss M. W., Schlesinger J. I. 1987; Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. Journal of Infectious Diseases 155:1198–1204
    [Google Scholar]
  19. Wertz G. W., Stott E. J., Young K. K. Y., Anderson K., Ball L. A. 1987; Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice. Journal of Virology 61:293–301
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-70-8-2185
Loading
/content/journal/jgv/10.1099/0022-1317-70-8-2185
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error